You are here

Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL156334-01
Agency Tracking Number: R43HL156334
Amount: $298,412.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA19-272
Timeline
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-01-01
Award End Date (Contract End Date): 2021-12-31
Small Business Information
800 E LEIGH ST
Richmond, VA 23219-1551
United States
DUNS: 116965051
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 David Light
 (804) 305-2594
 davidrlight@gmail.com
Business Contact
 JAMES BURNET
Phone: (804) 305-2594
Email: jburnett@illexcor.com
Research Institution
N/A
Abstract

Acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non-
cardiogenic respiratory failure and hypoxemia. Consequently, patients with ARDS have severe hypoxemia due
to a significant impairment of gas exchange, and the goal of supportive therapy is to prevent critical tissue
hypoxia, which can cause acute cardiac arrest and death, or have long-term neurologic consequences for
survivors. ARDS affects almost 200,000 individuals annually in the US, leading to andgt;3.5 million hospital days and
nearly 75,000 deaths. Despite developments in our understanding of protective ventilation strategies and modern
advanced life support techniques, such as extracorporeal membrane oxygenation (ECMO), mortality associated
with ARDS remains unacceptably high and has not improved appreciably in two decades. Indeed, the mainstay
of supportive therapy in the ICU includes improving arterial oxygen (O2) saturation by introducing supplemental
O2 and supporting respiration with mechanical ventilation, but there are limits to the capacity of such measures
to benefit patients. In fact, exposure to a high fraction of O2 may actually increase risk for mortality in critically ill
patients. Similarly, excessive distention from mechanical ventilation can exacerbate acute lung injury, although
the goal of protective lung ventilation is simply to offer mechanical support without inducing harm. Hence,
maximal therapy with supplemental O2 and mechanical ventilation is often not sufficient to sustain life until the
lungs recover. We propose a novel, paradigm shifting therapeutic strategy using a small molecule drug to
enhance supportive care measures and potentially limit the morbidity and mortality of ARDS. Our therapeutic
candidate, TD-7, a synthetic analog of the natural aromatic aldehyde vanillin, is a highly potent, short acting
allosteric modifier of hemoglobin (Hb) that increases the capacity of Hb to bind and transport O2 by stabilizing its
quaternary structure in a high O2-affinity state. This pharmacologic effect can improve the margin of safety by
increasing O2 saturation at critical PO2 levels and prevent acute desaturation events without requiring more
invasive mechanical ventilation or additional supplemental O2. This intervention also has the potential to delay
or even prevent the need for emergent ECMO. Importantly, preliminary evidence for this approach demonstrates
that improvements in arterial O2 saturation with high Hb O2 affinity do not compromise tissue O2 unloading and,
instead, effectively reduce tissue hypoxia during an ARDS insult. While preliminary studies establish aromatic
aldehyde-containing compounds, such as TD-7, as a promising clinical approach to ARDS, our ultimate goal is
to provide definitive evidence of efficacy in a high fidelity porcine ARDS model to support advancement of this
drug candidate to human clinical trials. This will be achieved in a step-wise approach: first, with the optimization
of intravenous formulation and delivery of TD-7 to achieve targeted in vivo pharmacodynamic effects (‘dose-
finding’) in mini-pigs in Phase I, and subsequently, with the performance of a definitive efficacy study to assess
oxygenation and prevention of tissue hypoxia in a porcine ARDS model in Phase II.Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition that can result in acute respiratory
failure and severe hypoxemia due to a significant impairment of gas exchange. ARDS affects approximately
200,000 individuals annually in the US, and, despite medical advances in the understanding of protective
ventilation strategies and modern life support techniques, leads to nearly 75,000 deaths, with an unacceptably
high mortality rate that has not improved in two decades. We propose the development of a novel aromatic
aldehyde-containing drug candidate, TD-7, which can increase the capacity of hemoglobin to bind and transport
oxygen, and therefore improve the margin of safety for ARDS patients without requiring more invasive
mechanical ventilation or additional supplemental oxygen, and hopefully also delay or prevent the need for
advanced life support techniques, such as extracorporeal membrane oxygenation (ECMO).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government